JAGUAR HEALTH, INC. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
JAGUAR HEALTH, INC. (JAGX) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $1.49 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-04-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-04-09
- JAGUAR HEALTH, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $903.46K, a 3028.65% increase year-over-year.
- JAGUAR HEALTH, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $445.67K, a 785.01% increase year-over-year.
- JAGUAR HEALTH, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $61.45K, a 154.50% increase year-over-year.
- JAGUAR HEALTH, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $74.54K, a 95.42% increase year-over-year.
- JAGUAR HEALTH, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $1.49M, a 949.38% increase from fiscal 2016.
- JAGUAR HEALTH, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $141.52K, a 45.23% decline from fiscal 2015.
- JAGUAR HEALTH, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $258.38K.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $903.46K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-09 | $1.35M derived: sum of 2 quarters · filed 2018-04-09 | $1.41M derived: sum of 3 quarters · filed 2018-04-09 | $1.49M 10-K · filed 2018-04-09 |
| 2017-09-30 | $445.67K 10-Q · filed 2017-11-20 | $507.11K derived: sum of 2 quarters · filed 2017-11-20 | $581.65K 10-Q · filed 2017-11-20 | $610.53K derived: sum of 4 quarters · filed 2018-04-09 |
| 2017-06-30 | $61.45K 10-Q · filed 2017-08-09 | $135.99K 10-Q · filed 2017-08-09 | $164.87K derived: sum of 3 quarters · filed 2018-04-09 | $215.22K derived: sum of 4 quarters · filed 2018-04-09 |
| 2017-03-31 | $74.54K 10-Q/A · filed 2017-06-23 | $103.42K derived: sum of 2 quarters · filed 2018-04-09 | $153.78K derived: sum of 3 quarters · filed 2018-04-09 | $177.92K derived: sum of 4 quarters · filed 2018-04-09 |
| 2016-12-31 | $28.88K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-09 | $79.23K derived: sum of 2 quarters · filed 2018-04-09 | $103.38K derived: sum of 3 quarters · filed 2018-04-09 | $141.52K 10-K · filed 2018-04-09 |
| 2016-09-30 | $50.36K 10-Q · filed 2017-11-20 | $74.50K derived: sum of 2 quarters · filed 2017-11-20 | $112.65K 10-Q · filed 2017-11-20 | $167.83K derived: sum of 4 quarters · filed 2017-11-20 |
| 2016-06-30 | $24.14K 10-Q · filed 2017-08-09 | $62.29K 10-Q · filed 2017-08-09 | $117.47K derived: sum of 3 quarters · filed 2017-08-09 | $195.14K derived: sum of 4 quarters · filed 2017-08-09 |
| 2016-03-31 | $38.15K 10-Q/A · filed 2017-06-23 | $93.33K derived: sum of 2 quarters · filed 2017-06-23 | $171.00K derived: sum of 3 quarters · filed 2017-06-23 | $234.14K derived: sum of 4 quarters · filed 2017-06-23 |
| 2015-12-31 | $55.19K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | $132.85K derived: sum of 2 quarters · filed 2017-02-15 | $195.99K derived: sum of 3 quarters · filed 2017-02-15 | $258.38K 10-K · filed 2017-02-15 |
| 2015-09-30 | $77.67K 10-Q · filed 2016-11-14 | $140.81K derived: sum of 2 quarters · filed 2016-11-14 | $203.19K 10-Q · filed 2016-11-14 | |
| 2015-06-30 | $63.14K 10-Q · filed 2016-08-15 | $125.53K 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | $62.39K 10-Q · filed 2016-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |